Reviva Pharmaceuticals Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Brilaroxazine showed robust, durable efficacy and a favorable safety profile in phase III trials for schizophrenia, outperforming historical antipsychotics and addressing key unmet needs. A second phase III trial is planned, with NDA submission targeted for 2028 and potential exclusivity to 2046.
-
Brilaroxazine showed robust, sustained efficacy and safety in phase III schizophrenia trials, with minimal relapse and superior differentiation versus current antipsychotics. A second confirmatory trial is planned, with NDA filing targeted for early 2028 and potential patent exclusivity to 2046.
-
Brilaroxazine is advancing to a pivotal phase III trial for schizophrenia, with a new formulation designed to extend patent life to 2046. Pending FDA feedback, the company aims to expand indications and regain Nasdaq compliance, supported by a strong financial position and major upcoming catalysts.
-
Brilaroxazine is advancing to a second phase III trial in schizophrenia, with a new formulation aimed at extending patent life to 2046. FDA feedback on the formulation switch is expected mid-year, and the trial is set to start in Q3, leveraging strong prior data and a solid financial runway.